| Literature DB >> 30220937 |
Imre Bard1, George Gaskell1, Agnes Allansdottir2, Rui Vieira da Cunha3, Peter Eduard4, Juergen Hampel5, Elisabeth Hildt6, Christian Hofmaier5, Nicole Kronberger7, Sheena Laursen4, Anna Meijknecht8, Salvör Nordal9, Alexandre Quintanilha3, Gema Revuelta10, Núria Saladié10, Judit Sándor11, Júlio Borlido Santos3, Simone Seyringer7, Ilina Singh12, Han Somsen8, Winnie Toonders13, Helge Torgersen14, Vincent Torre15, Márton Varju11, Hub Zwart13.
Abstract
Neuroenhancement involves the use of neurotechnologies to improve cognitive, affective or behavioural functioning, where these are not judged to be clinically impaired. Questions about enhancement have become one of the key topics of neuroethics over the past decade. The current study draws on in-depth public engagement activities in ten European countries giving a bottom-up perspective on the ethics and desirability of enhancement. This informed the design of an online contrastive vignette experiment that was administered to representative samples of 1000 respondents in the ten countries and the United States. The experiment investigated how the gender of the protagonist, his or her level of performance, the efficacy of the enhancer and the mode of enhancement affected support for neuroenhancement in both educational and employment contexts. Of these, higher efficacy and lower performance were found to increase willingness to support enhancement. A series of commonly articulated claims about the individual and societal dimensions of neuroenhancement were derived from the public engagement activities. Underlying these claims, multivariate analysis identified two social values. The Societal/Protective highlights counter normative consequences and opposes the use enhancers. The Individual/Proactionary highlights opportunities and supports use. For most respondents these values are not mutually exclusive. This suggests that for many neuroenhancement is viewed simultaneously as a source of both promise and concern.Entities:
Keywords: Empirical ethics; Neuroenhancement; Social values
Year: 2018 PMID: 30220937 PMCID: PMC6132847 DOI: 10.1007/s12152-018-9366-7
Source DB: PubMed Journal: Neuroethics ISSN: 1874-5490 Impact factor: 1.480
Mean, standard deviation and percentage in agreement with claims
| Claim | Mean (SD) | % Agree* |
|---|---|---|
| Neuro-enhancement should never be used on children | 8.0 (2.81) | 76 |
| It is essential that public authorities oversee and control neuro-enhancement | 7.7 (2.52) | 74 |
| People’s achievements should come from their own effort and not from pills and devices | 7.5 (2.57) | 69 |
| People need to be protected from pressures to use neuro-enhancers | 7.3 (2.51) | 66 |
| It is an expression of human nature to try to overcome the limitations of our body and mind | 7.2 (2.18) | 68 |
| Some people will use neuro-enhancers to cope with increasing demands in life | 7.2 (2.11) | 71 |
| People should be content with their talents and abilities and not use artificial means to improve their performance | 6.7 (2.85) | 57 |
| Neuro-enhancement will increase competition between people | 6.6 (2.64) | 58 |
| Neuro-enhancement will threaten social cohesion | 6.0 (2.76) | 45 |
| I can imagine neuro-enhancement opening up fascinating new opportunities | 5.9 (2.64) | 46 |
| Only people with a medical problem should have access to neuro-enhancement | 5.7 (2.97) | 45 |
| If a neuro-enhancer is safe, it should be available as a consumer product | 5.6 (3.00) | 43 |
| Neuro-enhancement should be available to all those who might want it | 4.8 (3.22) | 34 |
| As life gets more pressured, neuro-enhancement may be the only way out | 3.8 (2.83) | 21 |
*0, 1, 2, 3: disagree; 4, 5, 6: neutral; 7, 8, 9, 10: agree
Claims loading on societal protective and individual proactionary components
| Rotated Component Matrixa | ||
|---|---|---|
| Claim | Component | |
| Societal / Protective | Individual / Proactionary | |
| People should be content with their talents and abilities and not use artificial means to improve their performance | .708 | |
| People’s achievements should come from their own effort and not from pills and devices | .722 | |
| It is essential that public authorities oversee and control neuro-enhancement | .486 | |
| Only people with a medical problem should have access to neuro-enhancement | .591 | |
| People need to be protected from pressures to use neuro-enhancers | .571 | |
| Neuro-enhancement should never be used on children | .449 | |
| Neuro-enhancement will threaten social cohesion | .673 | |
| If a neuro-enhancer is safe, it should be available as a consumer product | −.469 | .567 |
| Neuro-enhancement should be available to all those who might want it | −.553 | .509 |
| It is an expression of human nature to try to overcome the limitations of our body and mind | .578 | |
| I can imagine neuro-enhancement opening up fascinating new opportunities | .678 | |
| Some people will use neuro-enhancers to cope with increasing demands in life | .653 | |
| As life gets more pressured, neuro-enhancement may be the only way out | .501 | |
| Neuro-enhancement will increase competition between people | .564 | |
aVarimax with Kaiser normalization, Coefficients below 0.4 suppressed
Cross tabulation of support for societal protective and individual proactionary values
| Individual/Proactionary value scale | ||||
|---|---|---|---|---|
| Societal/Protective Value Scale | 0–3.33 | 3.34–6.66 | 6.67–10 | Total |
| 0–3.33 | 0.2% | 0.3% | 1.8% | 2.3% |
| 3.34–6.66 | 0.8% | 19% | 17% | 36.8% |
| 6.67–10 | 5.1% | 40.7% | 15% | 60.8% |
| Total | 6.1% | 60% | 33.9% | 100% |
Employment context regression coefficients
| Employment Context | Model 1 | Model 2 | Model 3 |
|---|---|---|---|
| R-squared | 0.005 | 0.016 | 0.278 |
| Constant term | 3.191 (0.067) | 3.705 (0.113) | 2.193 (0.198) |
| Protagonist’s gender (Reference category Female) | 0.044 (0.060) | 0.052 (0.060) | 0.017 (0.051) |
| Protagonist’s performance Good (reference category Failing) | −0.355*** (0.060) | −0.347*** (0.060) | −0.284*** (0.051) |
| NE-technology Pill (reference category: Device) | 0.070 (0.060) | 0.068 (0.060) | 0.024 (0.051) |
| NE-efficacy High (reference category: Low) | 0.307*** (0.060) | 0.317*** (0.060) | 0.233*** (0.051) |
| Respondent is female (reference category: Male) | −0.491*** (0.060) | −0.306*** (0.052) | |
| Respondent age 25–34 (reference category 18–24) | 0.041 (0.116) | 0.016 (0.100) | |
| Respondent age 35–44 (reference category 18–24) | −0.202 (0.113) | −0.172 (0.097) | |
| Respondent age 45–54 (reference category 18–24) | −0.275* (0.113) | −0.204* (0.097) | |
| Respondent age 55+ (reference category 18–24) | −0.552*** (0.104) | −0.283*** (0.089) | |
| Respondent has a university degree (reference category: no degree) | −0.004 (0.068) | −0.101 (0.058) | |
| Societal/Protective scale (11-point scale) | −0.444*** (0.016) | ||
| Individual/Proactionary scale (11-point scale) | 0.759*** (0.017) |
Standard errors in parentheses
* p < 0.05; ** p < 0.01; *** p < 0.001
Model 1 includes the 4 experimental manipulations represented as dummy variables
Model 2 includes Model 1 plus sociodemographic indicators
Model 3 includes Model 2 and SP and IP scales
Education context regression coefficients
| Education | Model 1 | Model 2 | Model 3 |
|---|---|---|---|
| R-squared | 0.006 | 0.018 | 0.270 |
| Constant term | 3.580 (0.069) | 4.301 (0.117) | 2.668 (0.205) |
| Protagonist’s gender (Reference category Female) | −0.039 (0.062) | −0.039 (0.062) | 0.038 (0.053) |
| Protagonist’s performance Good (reference category Failing) | −0.274*** (0.053) | −0.286*** (0.062) | −0.206*** (0.053) |
| NE-technology Pill (reference category: Device) | −0.293*** (0.053) | −0.286*** (0.062) | −0.246*** (0.053) |
| NE-efficacy High (reference category: Low) | 0.336*** (0.053) | 0.341*** (0.062) | 0.298*** (0.053) |
| Respondent is female (reference category: Male) | −0.489*** (0.062) | −0.301*** (0.053) | |
| Respondent age 25–34 (reference category 18–24) | −0.199 (0.119) | −0.226* (0.103) | |
| Respondent age 35–44 (reference category 18–24) | −0.478*** (0.117) | −0.446*** (0.100) | |
| Respondent age 45–54 (reference category 18–24) | −0.433*** (0.116) | −0.363*** (0.100) | |
| Respondent age 55+ (reference category 18–24) | −0.802*** (0.107) | −0.531*** (0.092) | |
| Respondent has a university degree (reference category: no degree) | 0.042 | −0.054 (0.060) | |
| Societal/Protective scale (11-point scale) | −0.450*** (0.017) | ||
| Individual/Proactionary scale (11-point scale) | 0.764*** (0.017) |
Standard errors in parentheses
* p < 0.05; ** p < 0.01; *** p < 0.001
Model 1 includes the 4 experimental manipulations represented as dummy variables
Model 2 includes Model 1 plus sociodemographic indicators
Model 3 includes Model 2 and SP and IP scales
| Employment: |
Box 2 Claims about neuroenhancement
| In the survey, the following instructions were presented. “Here are some views that people have expressed about neuroenhancement of healthy individuals, and its wider implications for society. Please read the statements below and show how much you agree or disagree with them, using the scale provided (−5 to +5). |